U r not real gutboy. You must creat some email address such as gutboy09@ymail or others. Am I right.
If you are the real gutboy, u know my English skill. If u r the real gutboy, then u r not smart.
I know how to deal with u if u r ot real gutboy. Good luck.
No stupid doosh: you are wanting a 3-4 drop. Idiots like yourself don't think. How can you when you have no brain?
will you wake up one morning, open your acct to a zero balance, and have your online broker advise you that you must not have taken proper care of your password, and they are sorry, but they are not liable?
very creative indeed - as you can read in my Friday posts I bought 15k shares in after hours on the disclosure of the Discovery Capital stake in VELT and was also counting on good numbers from MM (as Oppenheimer promised) - but MM delivered a big disappointment and a dismal outlook and management remarks on the conference call weren't exactly upbeat so I decided to exit the Velti position with a loss here as MM's commentary doesn't bode well for a player as weak as Velti.
you are the best chosenfew1996
TLSR: Would tell me some of the names that you like?
GW: I'll start with Oncolytics Biotech Inc. (ONCY:NASDAQ; ONC:TSX). Some interesting data were reported on Dec. 13, and the year finished with the company deciding that its phase 3 head-and-neck cancer trial, REO 018 (Reolysin [reovirus serotype 3—Dearing strain] in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head-and-neck cancers), has been effectively split into two different studies. One side focuses on patients with distal metastatic disease, and the other on those with locoregional recurrence, with or without distant metastatic disease. Data for progression-free survival and overall survival is expected in Q2/13.
"Money is being put to work in healthcare stocks, and we are optimistic that will continue."
Subsequently, some initial analysis was completed that suggested a positive differential effect on tumor size, and on the percentage of patients with a positive result, at an early point in the experimental arm of the study. It is a somewhat novel analysis, and because it was double-blinded, randomized data, I think it caused investors to be enthusiastic about the potential that this was an early indication of the drug working. This was actually the first endpoint to be un-blinded in REO 018.
Now we are a quarter or so away from release of important information from the phase 3 trial, which we are expecting in Q2/13. We continue to be encouraged by the potential for the drug and are very eager to see how this phase 3 study turns out.
TLSR: It's an interesting idea to look at the effect of Reolysin on distal metastatic lesions versus those that may not have metastasized as yet. These tumor colonies have different phenotypes. Do you think that's a good design?
GW: Anything that can be done to make a more homogeneous study population is likely to assist in discerning a difference. If you have an inhomogeneous group of folks, there may be important differences that aren't notable across the breadth of that group. I think this is an appropriate way to improve the chance of success for the study.
TLSR: When we spoke last, in August, we talked briefly about the difficulty of this squamous cell carcinoma of the head-and-neck indication. It is so aggressive and generally difficult to deal with, both medically and surgically. It is disfiguring, and patients lose their ability to eat. I say any progress or improvement in efficacy is good. But these recent data, while statistically significant, aren't dramatic. How will Reolysin stack up against cetuximab (Erbitux)? Does it have to show superiority or just noninferiority?
GW: We won't be able to do a direct comparison because they are different studies. There is no reason to believe that Oncolytics' approach would be exclusive of cetuximab. For investors, it is about getting that first randomized data showing that there is a treatment effect, because we believe that the disease indication and market opportunity are very broad for Reolysin. We are not going to hold up a glass right now to see whether it's better or worse than cetuximab, although some investors might look at that as being important relative to the opportunity in head-and-neck cancer treatments.
TLSR: These clinical trials with Reolysin are so numerous. It looks like maybe 30 trials are going on in the U.S., in Canada and in the U.K. How is the company funding all of these?
GW: A number of the ongoing studies for Reolysin are being sponsored by the National Cancer Institute. That is offsetting a tremendous amount of the cost. I believe about 10 studies are sponsored.
TLSR: Is the phase 3 data on Reolysin the next catalyst for Oncolytics? And what is your target price?
GW: Yes, that is the next catalyst. We expect data in Q2/13: It might slip into Q3. My target price is $11.
Look at their 2012 guidance back in Feb 2012, they were spot on except for Rev which was down a bit....keep shorting, it will really hurt when they bend you over and start pounding away!!!!!
LONG LIVE THE KING!
Sentiment: Strong Buy
Same thing you posted on sunpower(SPWR) when it was 5. Now, SPWR is in teens and raising.
SPWR traded below PWER and thanks you shorts like you, SPWR and FSLR fly through 52 week highs. Same thing will happen here.
i never said today that i will sell. I am just pointing out what it is doing. I am long and do think there will be more good news around the corner.
The only things that have a tendency to show up in AMRN are massive insider sales and a frefalling share price! LMFAO:)
Did O'bama state that from the Golf course in Florida with Tiger??
A little break in the IDR's at about 66 cents per Q. ATLS will give back $3.75 million per Q after receiving $7 million in IDR's. So 66 to about 72 cents a share in reality have zero IDR's.
I think the ramp will be as Statestrip has indicated or maybe a little higher with 4th Q distribution paid in 1st Q 2014 of up to 75 cents a share. A lot of items do not fully hit the bottom line until mid year and 4th Q. Pioneer drilling big ramp starts in July area and wells do not start impacting production for a 3 month lag. Fee service on the 60 plant in Velma takes affect July 1. Kicker will be any strength in propane, ethane and natural gas.
That was from 1/31 numbers. The thing to look at is that over 3 million shrs were short in September when the Bloomberg article came out. Those shorts are covering now and expect it to continue for atleast a few more weeks. Low volume stocks go crazy when shorts rush to the exits. I wouldnt sell anything below $24. Goodluck
Sentiment: Strong Buy